...
首页> 外文期刊>Gastroenterology Research >Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital
【24h】

Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital

机译:粪便微生物群移植用于多种合并症患者的复发性梭菌性感染:高级护理社区医院的长期安全性和疗效结果

获取原文
           

摘要

Background: Cure rates of Clostridium difficile infection (CDI) with fecal microbiota transplant (FMT) have been promising. However, there is debate regarding success of FMT in patients with comorbidities. Methods: Electronic chart review was done to collect data on patients who underwent FMT from January 2015 to August 2017. Charts were analyzed in November 2018 with a median follow-up of 25.4 months (interquartile range 20 - 31 months). Results: Twenty patients underwent FMT. The primary success rate at our institution was 90% and overall success rate was 100%. Six patients (43%) had FMT failure (two early and four late). Conclusions: This case series is a description of our center’s initial experience with FMT for treatment of recurrent CDI. Our high success rate reiterates the efficacy and safety of FMT in this population including patients with comorbidities.
机译:背景:菌梭菌感染(CDI)的固化速率与粪便微生物群移植(FMT)一直很有前途。但是,有关合并症患者的FMT成功存在争论。方法:电子图表审查是为从2015年1月到2017年1月到8月的FMT接受FMT的患者的数据。2018年11月分析图表,中位随访25.4个月(四分位数20 - 31个月)。结果:二十名患者接受了FMT。我们机构的主要成功率为90%,总体成功率为100%。六名患者(43%)患有FMT失败(早期和4次)。结论:本案例系列是我们中心初始经验的初步体验,用于治疗经常性CDI。我们的高成功率重申了该人群中FMT的疗效和安全性,包括患有可融合的患者。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号